DYLAN DEMARS: Open Payments
NPI 1619575818 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,949 in 69 payments from 15 companies in 2025. Trend: 2023 $13,409 · 2024 $5,292 · 2025 $3,949
Speaker / faculty: $2,750Food & beverage: $1,199
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $2,962 |
| Axsome Therapeutics, Inc. | 8 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $132 |
| Neurocrine BioSciences, Inc. | 5 | $122 |
| Alkermes, Inc. | 5 | $110 |
| Supernus Pharmaceuticals, Inc. | 5 | $75 |
| E.R. Squibb & Sons, L.L.C. | 4 | $71 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| Tris Pharma Inc | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
Products named: VRAYLAR, Auvelity, INGREZZA, ARISTADA, FANAPT, Qelbree, COBENFY, Jornay PM.
Industry payments across FL — which companies pay providers there.
